SCHEMBL10090322

SCHEMBL10090322

CN(CCOc1ccc(Br)cc1/C=C1\SC(=S)NC1=O)C(=O)COc1ccc(Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTP4A3 O75365 7/20 0.54
▸ GSK3B P49841 1/20 0.46
▸ MGAM O43451 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ SI P14410 1/20 0.45
▸ MGAM2 Q2M2H8 1/20 0.45
▸ PTGES O14684 2/20 0.45
▸ ADAMTS5 Q9UNA0 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ POLB P06746 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ GPR35 Q9HC97 1/20 0.43
▸ PLA2G1B P04054 1/20 0.42
▸ DNMT1 P26358 1/20 0.42
▸ GFER P55789 1/20 0.42
▸ ATG4B Q9Y4P1 1/20 0.42
▸ CRHBP P24387 1/20 0.42
▸ CRHR2 Q13324 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ PDE4B Q07343 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2065392 1.00 PTP4A3 (0.54) PTP4A3GSK3BMGAMGAASI
SCHEMBL10090285 0.85 PTP4A3 (0.66) PTP4A3GSK3BMGAMGAASI
SCHEMBL2065011 0.85 PTP4A3 (0.66) PTP4A3GSK3BMGAMGAASI
SCHEMBL2065355 0.84 PTP4A3 (0.61) PTP4A3GSK3BCA2PDE4BPDE3A
SCHEMBL10090319 0.84 PTP4A3 (0.61) PTP4A3GSK3BCA2PDE4BPDE3A
SCHEMBL14464062 0.84 PTP4A3 (0.64) PTP4A3GSK3BMEN1POLBKMT2A
SCHEMBL2065357 0.84 PTP4A3 (0.61) PTP4A3GSK3BMEN1POLBKMT2A
SCHEMBL14464067 0.83 PTP4A3 (0.60) PTP4A3GSK3BPDE4BPDE3A
SCHEMBL2065103 0.81 PTP4A3 (0.57) PTP4A3GSK3BMEN1KMT2APDE4B
SCHEMBL10090186 0.81 PTP4A3 (0.57) PTP4A3GSK3BMEN1KMT2APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148541-B2 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2012-04-03 — — US disclosed
US-8148541-B2 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2012-04-03 — — US disclosed
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-02-12 — — US disclosed
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same PTPRR, PTPRG, PTPRS PTP4A3 28/4885GSK3B 390/4885MGAM 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback